Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2020

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This is a prospective, single-arm study to investigate the efficacy and safety of the combination of fixed low-dose eltrombopag plus recombinant human thrombopoietin (rhTPO) as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients during the COVID-19 pandemic.
Epistemonikos ID: c980bcff4e45aab065777c810151bf1d6ac75a29
First added on: Jul 25, 2023